Stereotactic ablative radiotherapy (SABR) using 70Â Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications

SABR with 70 Gy in 10 fractions appears to achieve excellent local control and acceptable toxicity for clinically challenging cases with improved tolerance of the chest wall and brachial plexus as compared with 50 Gy in 4 fractions. This regimen may not be suitable in patients with tumor invading critical central structures. More studies are needed to validate our conclusions.